Living with Multiple Sclerosis means dealing with an unpredictable disease that affects the nerves. Doctors are looking for better ways to track how much damage is happening in real time. A new blood test measuring a protein called sNfL shows promise as a way to see recent nerve injury and predict future tissue loss or disability risk.
While this blood test is useful, it has some important limits. It is not specific only to Multiple Sclerosis and its levels change based on a person's age. Because of these factors, doctors should not use one single blood test result to make big changes to a treatment plan. Instead, they use it as an extra piece of information alongside MRI scans and regular checkups.
To get the most accurate picture, doctors look at how sNfL levels change over time rather than just one measurement. When combined with another marker called sGFAP, these tests can help clarify what is happening when a patient's disability worsens even when inflammation seems low.
Common questions
What is sNfL and how does it help patients?
sNfL is a protein found in the blood that acts as a marker for recent nerve injury. For people with Multiple Sclerosis, higher levels or rising trends of this protein can be linked to inflammatory activity, how well a treatment is working, and the risk of future tissue loss or disability.
Can a single blood test tell everything about my condition?
No, a single measurement cannot be used alone to change your treatment. Because sNfL levels are affected by age and other health factors, doctors need to look at several measurements over time. It is meant to support other tools like MRI scans and clinical exams rather than replacing them.
How does this test differ from other markers?
While sNfL shows recent nerve injury, another marker called sGFAP tracks long-term changes in brain cells. Using both together can help doctors better understand why a patient's disability might be getting worse even when there is very little active inflammation.
